调血脂药对3T3-L1脂肪细胞脂肪水孔蛋白mRNA表达的影响

Effects of blood lipid-regulating drugs on AQPap mRNA expression in 3T3-L1 adipocytes

目的 通过细胞培养研究非诺贝特、洛伐他汀对成熟脂肪细胞脂肪水孔蛋白 (aquaporinadipose,AQPaP)基因表达的影响 ,了解调脂药对AQPaP基因表达有无影响 ,探讨其在肥胖及糖尿病发病中所起作用以及调脂药的药理作用机制。方法 以 10 0 μmol/L、2 5 0 μmol/L非诺贝特及 10 μmol/L洛伐他汀刺激诱导分化第 9天的 3T3 L1脂肪细胞 4 8h ,提取细胞RNA ,运用半定量反转录聚合酶链反应技术 ,检测AQPapmRNA表达量的变化。结果 10 0 μmol/L非诺贝特刺激脂肪细胞 4 8h后 ,AQPapmRNA表达量有所增加 ,浓度升至 2 5 0 μmol/L ,AQPapmRNA表达量又有下降 ,但各组之间差异无显著性 (P >0 0 5 )。 10 μmol/L洛伐他汀刺激 3T3 L1脂肪细胞4 8h ,与对照组相比 ,AQPapmRNA表达量略有下降 ,但差异无显著性 (P >0 0 5 )。与非诺贝特刺激组相比差异也无显著性差异 (P >0 0 5 )。结论 非诺贝特对脂肪细胞AQPaP基因表达无直接作用。而洛伐他汀对AQPap基因表达也无影响 ,AQPap可能是过氧化物酶体增生剂激活受体 γ(PPAR γ)

Objective Aquaporin adipose (AQPap) is the physiological glycerol channel specific to adipocytes,and it is expressed predominantly in adipose tissue.In this study,we investigated the effect of blood lipid reulating drugs such as feno fibrate and lovastatin on expression of AQPap in 3T3 L1 adipocytes,so as to know the role of AQPap in obesity and diabetes mellitus and the pharmacological mechanism of these drugs on blood lipid regulation.Methods The differentiated 3T3 L1 adipocytes were incubated with 100 μmol/L,250 μmol/L fenofibrate for 48 hours,or stimulated with 10 μmol/L lovastatin for 48 hours,then total cellular RNA was extracted,and the expression of AQPap mRNA was detected by RT PCR.Results There was no significant change in AQPap mRNA levels under the treatment with various concentrations of fenofibrate ( P >0 05) After stimulation with 10 μmol/L lovastatin,AQPap mRNA expression was decreased,but there was no significant change compared with control or the fenofibrate stimulation group.Conclusion Fenofibrate,one of the hypolipidemic drugs,has no significant effect on the expression of AQPap mRNA levels in 3T3 L1 adipocytes,neither does lovastatin,supposing that maybe AQPap is one of the downstream genes of PPAR γ